Zobrazeno 1 - 10
of 13
pro vyhledávání: '"L E, Flaherty"'
Publikováno v:
Cancer. 91(6)
Some studies have suggested that women with metastatic malignant melanoma have a better survival rate than men. However, little is known about the effect of gender on survival in combination with other clinical variables and treatment variables. Thus
Publikováno v:
Cancer. 89(2)
Preclinically, paclitaxel given according to an intense bolus schedule has significant antitumor activity against human prostate carcinoma cell lines in SCID mice. The authors evaluated the feasibility and efficacy of weekly 1-hour infusion of paclit
Autor:
V K, Sondak, L E, Flaherty
Publikováno v:
Cancer journal (Sudbury, Mass.). 6(3)
Autor:
L E, Flaherty
Publikováno v:
The cancer journal from Scientific American. 6
The modest activity of chemotherapy and biologic agents in the treatment of advanced metastatic melanoma has prompted investigators to consider combinations of chemotherapy and biologic agents (i.e., biochemotherapy) as a way of improving response ra
Autor:
V K, Sondak, P Y, Liu, L E, Flaherty, W S, Fletcher, P, Periman, D R, Gandara, S A, Taylor, S P, Balcerzak, F L, Meyskens
Publikováno v:
The cancer journal from Scientific American. 5(1)
Interferon alfa has modest but definite activity in the treatment of metastatic melanoma and is the only agent currently available for adjuvant therapy of high-risk resected disease. A variety of retinoic acid derivatives have been shown to be synerg
Autor:
M K, Wallack, M, Sivanandham, C M, Balch, M M, Urist, K I, Bland, D, Murray, W A, Robinson, L E, Flaherty, J M, Richards, A A, Bartolucci
Publikováno v:
Cancer. 75(1)
In a Phase II trial, surgical adjuvant active specific immunotherapy using a live vaccinia virus-augmented allogeneic polyvalent melanoma cell lysate, vaccinia melanoma oncolysate (VMO), produced a significant disease free interval (DFI) in patients
Publikováno v:
Cancer. 74(1)
Hormone-refractory prostate cancer generally remains a chemotherapy-resistant tumor and therefore warrants the continued evaluation of promising agents.Twenty-two eligible patients with hormone-refractory prostate cancer were treated with oral etopos
Autor:
L E, Flaherty, W, Robinson, B G, Redman, R, Gonzalez, S, Martino, M, Kraut, M, Valdivieso, A R, Rudolph
Publikováno v:
Cancer. 71(11)
Based on prior experience with dacarbazine (DTIC) and an outpatient interleukin-2 (IL-2) regimen, the current study was conducted to improve the antitumor efficacy and assess the immunologic interactions between chemotherapy and IL-2.Thirty-two patie
Autor:
L E, Flaherty, B G, Redman, G G, Chabot, S, Martino, S M, Gualdoni, L K, Heilbrun, M, Valdivieso, E C, Bradley
Publikováno v:
Cancer. 65(11)
Because of encouraging response rates published with recombinant interleukin-2 (rIL-2) alone in metastatic malignant melanoma (MMM), dacarbazine (DTIC) and rIL-2 were sequentially combined to evaluate efficacy, toxicity, pharmacokinetics, and immunol
Publikováno v:
AJR. American journal of roentgenology. 154(2)
Interleukin-2 is receiving widespread interest as an immunotherapeutic agent in the treatment of certain cancers. Severe arthralgias recently have been reported as a significant side effect, and the cause of pain is unknown. Because interleukin-2 is